Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
M Camilleri - Clinical Pharmacology & Therapeutics, 2012 - search.ebscohost.com
Clinical Pharmacology & Therapeutics, 2012•search.ebscohost.com
The article reports on the new therapeutic options being developed for lower gastrointestinal
(GI) motility disorders and irritable bowel syndrome. It states the therapeutic options for
constipation activate diverse mechanisms to induce increased motility or secretion in both
the small bowel and the colon. It states new treatments also target excessive secretion in
patients with chronic diarrhea, visceral pain, and the lower GI functional disorders.
(GI) motility disorders and irritable bowel syndrome. It states the therapeutic options for
constipation activate diverse mechanisms to induce increased motility or secretion in both
the small bowel and the colon. It states new treatments also target excessive secretion in
patients with chronic diarrhea, visceral pain, and the lower GI functional disorders.
Abstract
The article reports on the new therapeutic options being developed for lower gastrointestinal (GI) motility disorders and irritable bowel syndrome. It states the therapeutic options for constipation activate diverse mechanisms to induce increased motility or secretion in both the small bowel and the colon. It states new treatments also target excessive secretion in patients with chronic diarrhea, visceral pain, and the lower GI functional disorders.
search.ebscohost.com